Stevens A, Weller M, Wiethölter H
Department of Neurology, University of Tübingen, Germany.
Acta Neurol Scand. 1992 Nov;86(5):485-9. doi: 10.1111/j.1600-0404.1992.tb05129.x.
The authors determined CSF and serum IgG and IgM antibodies to seven gangliosides in 48 patients with multiple sclerosis. Differing ganglioside antibody patterns in CSF but not serum allowed to reclassify 93% of MS patients correctly when compared to patients with Guillain-Barré syndrome or neuroborreliosis. This suggest that the antibody patterns are neither random nor alike in inflammatory diseases of the nervous system. CSF ganglioside antibody titres were found to be different for patients with relapsing remitting (RRMS; n = 35) and chronic progressive (CPMS; n = 13) multiple sclerosis. Our study reveals characteristic ganglioside antibody patterns in MS and confirms previous evidence of disturbed immunoregulation in MS.
作者测定了48例多发性硬化症患者脑脊液和血清中针对七种神经节苷脂的IgG和IgM抗体。与吉兰-巴雷综合征或神经莱姆病患者相比，脑脊液中不同的神经节苷脂抗体模式而非血清中的抗体模式能够正确地对93%的多发性硬化症患者进行重新分类。这表明在神经系统炎症性疾病中，抗体模式既不是随机的也不相同。发现复发缓解型（RRMS；n = 35）和慢性进展型（CPMS；n = 13）多发性硬化症患者的脑脊液神经节苷脂抗体滴度不同。我们的研究揭示了多发性硬化症中特征性的神经节苷脂抗体模式，并证实了先前关于多发性硬化症免疫调节紊乱的证据。
